Overview

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
0
Participant gender:
All
Summary
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Gilead Sciences
Collaborator:
Astellas Pharma US, Inc.
Treatments:
Adenosine
Regadenoson
Criteria
Inclusion Criteria:

- Referred for a clinically indicated pharmacological stress SPECT myocardial perfusion
imaging study

Exclusion Criteria:

- Any condition precluding the safe administration of Adenoscan for a SPECT myocardial
perfusion imaging study

- Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method
of birth control